中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

47 records (took 0.023 seconds)

    POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY
    1.
    发明申请
    POTASSIUM CHANNEL MODULATORS AND PLATELET PROCOAGULANT ACTIVITY 审中-公开
    钾通道调节剂和片剂加工活性

    公开(公告)号：WO2007112367A3

    公开(公告)日：2008-01-24

    申请号：PCT/US2007064956

    申请日：2007-03-26

    Applicant: PORTOLA PHARM INC ,  ZWAAL ROBERT F A ,  CONLEY PAMELA B

    Inventor： ZWAAL ROBERT F A ,  CONLEY PAMELA B

    IPC: A61K31/41 ,  A61K38/00

    CPC classification number: A61K31/4745

    Abstract: Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca 2 +-sensitive K + channels, or Gardos channels, preferably while maintaining platelet bleeding arrest function, may be used to treat a variety of disorders.

    Abstract translation: 本文教导了调节血小板促凝血反应的方法。 可以使用抑制抑制Ca 2+ 2敏感性高通道或Gardos通道的药物对血小板促凝血反应的抑制，优选在维持血小板渗血阻滞功能的同时治疗 各种疾病。

    TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY
    3.
    发明申请
    TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY 审中-公开
    目标交付和表达程序化学活动

    公开(公告)号：WO2008121721A3

    公开(公告)日：2009-01-08

    申请号：PCT/US2008058469

    申请日：2008-03-27

    Applicant: PORTOLA PHARM INC ,  SIMS PETER J ,  CONLEY PAMELA B ,  LUAN PENG ,  PHILLIPS DAVID R

    Inventor： SIMS PETER J ,  CONLEY PAMELA B ,  LUAN PENG ,  PHILLIPS DAVID R

    IPC: A61K9/127

    CPC classification number: A61K9/1271 ,  A61K9/1272 ,  A61K31/685 ,  A61K38/177 ,  A61K38/46 ,  A61K47/6843 ,  A61K47/6913 ,  A61K2300/00

    Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.

    Abstract translation: 包含含有磷脂酰丝氨酸或另一促凝血素（促凝血素）磷脂的大单层脂质囊泡的血小板替代物，对血管损伤时暴露于血管壁的胶原蛋白或其他成分具有结合亲和力的蛋白质和/或磷脂类 ，已经开发。 该血小板替代物提供了通过靶向粘附到血管损伤时暴露于胶原或其它组分的选择性地将促凝血磷脂和/或脂肪酸输送到血管损伤部位的手段。 由于靶向促凝血小泡与损伤部位的结合，并且触发表面上的磷脂酰丝氨酸（PS）的暴露，这些是特别有效的。

    TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY
    4.
    发明申请
    TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY 审中-公开
    靶向输注和促渗血管活性的表达

    公开(公告)号：WO2008121721A8

    公开(公告)日：2009-07-30

    申请号：PCT/US2008058469

    申请日：2008-03-27

    Applicant: PORTOLA PHARM INC ,  SIMS PETER J ,  CONLEY PAMELA B ,  LUAN PENG ,  PHILLIPS DAVID R

    Inventor： SIMS PETER J ,  CONLEY PAMELA B ,  LUAN PENG ,  PHILLIPS DAVID R

    IPC: A61K9/127

    CPC classification number: A61K9/1271 ,  A61K9/1272 ,  A61K31/685 ,  A61K38/177 ,  A61K38/46 ,  A61K47/6843 ,  A61K47/6913 ,  A61K2300/00

    Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.

    Abstract translation: 由含有磷脂酰丝氨酸或另一种促凝血（促凝血）磷脂的大单层脂质囊泡组成的血小板替代物，对血管损伤时暴露的胶原或血管壁的其他成分具有结合亲和力的蛋白质和/或磷脂酶 ， 已经被开发出来。 该血小板替代物提供了通过靶向粘附胶原蛋白或血管损伤时暴露的其他成分，将促凝血磷脂和/或脂肪酸选择性递送至血管损伤部位的手段。 由于将促凝血囊泡靶向损伤部位并引发表面上的磷脂酰丝氨酸（PS）暴露，这些特别有效。

    Preparación de derivados del factor xa
    6.
    发明专利
    Preparación de derivados del factor xa 未知

    公开(公告)号：CO2019000120A2

    公开(公告)日：2019-03-29

    申请号：CO2019000120

    申请日：2019-01-09

    Applicant: PORTOLA PHARM INC

    Inventor： KARBARZ MARK ,  CONLEY PAMELA B ,  LU GENMIN

    IPC: C12N9/64 ,  C07K1/22

    Abstract: La presente descripción proporciona métodos para fabricar una proteína derivada de fXa a gran escala, lo que produce un alto rendimiento de producto proteico altamente puro. El método puede incluir agregar un detergente a una muestra que contiene una construcción de polinucleótidos que codifica la proteína y purifica la proteína a través de un cromatógrafo por afinidad basado en el inhibidor la tripsina de soja (STI), un cromatógrafo de modo mixto y de intercambio de iones y una interacción hidrofóbica.

    PREPARATION OF FACTOR XA DERIVATIVES
    7.
    发明专利
    PREPARATION OF FACTOR XA DERIVATIVES 未知

    公开(公告)号：CA3027457A1

    公开(公告)日：2017-12-21

    申请号：CA3027457

    申请日：2017-06-19

    Applicant: PORTOLA PHARM INC

    Inventor： KARBARZ MARK ,  CONLEY PAMELA B ,  LU GENMIN

    IPC: C12N9/64 ,  C07K1/22

    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.

    COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR
    8.
    发明专利
    COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR 未知

    公开(公告)号：NZ599556A

    公开(公告)日：2013-10-25

    申请号：NZ59955608

    申请日：2008-05-02

    Applicant: PORTOLA PHARM INC

    Inventor： CONLEY PAMELA B

    IPC: A61K45/06 ,  A61K31/235 ,  A61K31/422 ,  A61K31/435 ,  A61K31/517 ,  A61P7/00 ,  A61P7/02 ,  A61P9/00

    Abstract: Abstract - 599556 Disclosed herein is the use of a first therapeutic agent of [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2Hquinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a condition in a mammal selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary arteryl bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prosthesis, wherein the medicament is for administration in combination with a second therapeutic agent which is selected from the group consisting of a specific inhibitor of thrombin, a P-selectin inhibitor, a specific inhibitor of factor XIIa, low molecular weight heparin, acenocoumarol, clorindione, dicumarol, diphenadione, ethyl biscoumacetate, phenprocoumon, phenindione, tioclomarol, an anti-tissue factor antibody, fragmin, NAP-5, rNAPc2, a P2Y12 receptor antagonist, a tissue factor pathway inhibitor, ramatroban, terbogrel, (3-{ 6-[(4-chlorophenylsulfonyl)amino]-2-methyl-5,6,7,8-tetrahydronaphth-1-yl} propionic acid, ethyl (1R,3aR,4aR,6R, 8aR, 9S, 9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-C] furan-6-ylcarbamate, 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ibuprofen, a beta blocker, a calcium channel blocker and PSGL-1.

    COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR
    9.
    发明专利
    COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR 未知

    公开(公告)号：NZ581324A

    公开(公告)日：2012-05-25

    申请号：NZ58132408

    申请日：2008-05-02

    Applicant: PORTOLA PHARM INC

    Inventor： CONLEY PAMELA B ,  ANDRE PATRICK ,  SINHA UMA

    IPC: A61K31/235 ,  A61K31/422 ,  A61K31/435 ,  A61K31/517 ,  A61K45/06 ,  A61P7/00 ,  A61P7/02 ,  A61P9/00

    Abstract: Disclosed herein is the use of a first therapeutic agent of [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2Hquinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a condition in a mammal selected from the group consisting of acute myocardial infarction, stable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary arteryl bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prosthesis, wherein the medicament is for administration in combination with a second therapeutic agent which is selected from the group consisting of betrixaban, a specific inhibitor of factor IXa, a specific inhibitor of factor XI, a specific inhibitor of factor XIa, a specific inhibitor of factor VIIa, YM-150, Daiichi DU-176b, N-{ (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl} -1H-indole-6-carboxamede, apixaban, rivaroxaban, otamixaban, razaxaban, AZD0837, RB2006, ximelagatran, dabigatran, bivalirudin, argatroban, phenocoumarol, synthetic pentasaccharides, such as fondaparinux, idraparinux, biotinylated idraparinux; abciximab, eptifibatide, tirofiban, dipyridamole, Aggrenox, cilostazol, ifetroban, isogrel, furegrelate, resveratrol, ozagrel, an anticoagulant agent and an antiplatelet agent.

Patent Agency Ranking